CLAIMS

1. A cosmetic method for treating moderate to severe glabellar lines (GL) and/or lateral canthal lines (LCL) in a human subject, comprising administering a liquid composition that comprises from 10 to 200 LD50 units of botulinum neurotoxin (BoNT) per mL,

wherein said liquid composition further comprises:

a) sodium chloride at a concentration of 100-300 mM, and potassium chloride at a concentration of 1-25 mM,

b) at least one source of phosphate ions, selected from, sodium phosphate, potassium phosphate, di-sodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate dihydrate, and another source of phosphate ions at a concentration of 1 to 50 mM;

c) polysorbate at a concentration of 0.1-1.5% (v/v); and

d) at least one D- or L-amino acid at a concentration of 0.75-2.25 mg/mL, selected from, alanine, valine, leucine, serine, threonine, lysine, histidine, tryptophan, aspartic acid, and glutamic acid,

wherein the liquid composition has a pH between 6.0 and 7.5;

wherein the subject receives multiple injections of said composition in the glabellar region for treating GL; and/or

wherein the subject receives multiple injections of said composition below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim, for treating LCL.

2. The cosmetic method of claim 1, wherein the amino acid is in the L isoform.

3. The cosmetic method of claim 1 or claim 2, wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin types A, B, C, D, E, F and G; preferably wherein the botulinum neurotoxin is botulinum neurotoxin type A.

4. The cosmetic method of any one of the preceding claims, wherein the pH of the liquid composition is between 6.6 and 6.9.

5. The cosmetic method of any one of the preceding claims, wherein the osmolality of the liquid composition is between 270 mOsm/kg and 310 mOsm/kg.

6. The cosmetic method of any one of the preceding claims, wherein between 10 and 100 LD50 units of botulinum toxin is administered to the subject; optionally wherein:

a) between 10 and 75 LD50 units of botulinum toxin is administered to the subject;

b) between 25 and 75 LD50 units of botulinum toxin is administered to the subject; or

c) 10, 25, 30, 45, 50, 60, 75, or 90 LD50 units of botulinum toxin is administered to the subject.

7. The cosmetic method of any one of the preceding claims, wherein the liquid composition is administered by subdermal, transdermal, intradermal or intramuscular injection; optionally

wherein the subject is injected multiple times in the glabellar region.

8. The cosmetic method of claim 7, wherein adjacent injections are separated by 0.5 to 10 cm; or wherein adjacent injections are separated by 1.5 to 3 cm.

9. The cosmetic method of any one of claims 7-8, wherein the injections are in the procerus muscle and the corrugator supercilii muscles on each side of the face, optionally wherein the injections are first made in the procerus muscle followed by the corrugator supercilii muscles on each side of the face, moving outwards from the median.

10. The cosmetic method of any one of claims 7-9, wherein all the injections are about 1 cm above the upper orbital rim and internal to the mid-pupillary lines; and/or

wherein all the injections are at least 1 cm above the central eyebrow or the bony supraorbital ridge; and/or

further comprising applying pressure on the upper orbital rim while injecting to minimize risks of regional effect of the botulinum neurotoxin.

11. The cosmetic method of claim 7, wherein the subject is injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.

12. The cosmetic method of any one of the preceding claims, wherein said treatment is repeated at intervals from 1 month to 6 months to inhibit said recurrence; optionally

wherein said treatment is repeated at intervals from 3 months to 6 months to inhibit said recurrence; or

wherein said treatment is repeated at intervals of 4 months to inhibit said recurrence.